Core Insights - Guofa Co., Ltd. (600538) has announced the appointment of a special auditing firm for a simplified procedure to issue A-shares to specific investors, with a total financing amount not exceeding 300 million yuan [1] - The company is focused on the health sector, covering pharmaceutical manufacturing, distribution, and IVD (in vitro diagnostics) [1] - A new diversified executive team has been established, including Chairman Jiang Ye and President Zhang Xiaowei, to drive the company's new development strategy [1] Company Developments - The IVD industry is transitioning from "single testing" to "precision and full-cycle management," with companies having core technological breakthroughs and global integration advantages becoming more competitive [1] - Guofa's subsidiary, Gao Sheng Bio, has developed an ultra-micro DNA automatic extraction workstation, enhancing automation in sample preparation and achieving success in forensic DNA second-generation sequencing library construction [1] - The company plans to focus on brand marketing for its eye drop product "Haibao" this year, which is recognized as a key technological innovation project and included in the national medical insurance and essential drug list [2] Strategic Initiatives - In late July, Chairman Jiang Ye led a visit to DaoKe Technology, a leading cloud-native operating system company, signaling the company's exploration into the AI field [2]